CL2023000532A1 - Derivado de nitrilo que actúa como inhibidor de la dipeptidil peptidasa 1 y su uso - Google Patents

Derivado de nitrilo que actúa como inhibidor de la dipeptidil peptidasa 1 y su uso

Info

Publication number
CL2023000532A1
CL2023000532A1 CL2023000532A CL2023000532A CL2023000532A1 CL 2023000532 A1 CL2023000532 A1 CL 2023000532A1 CL 2023000532 A CL2023000532 A CL 2023000532A CL 2023000532 A CL2023000532 A CL 2023000532A CL 2023000532 A1 CL2023000532 A1 CL 2023000532A1
Authority
CL
Chile
Prior art keywords
dipeptidyl peptidase
nitrile derivative
inhibitor
acts
diseases
Prior art date
Application number
CL2023000532A
Other languages
English (en)
Inventor
Li Yao
Shi Zongjun
Zhang Guobiao
Chen Lei
Wang Wenjing
Zhang Xiaobo
Zheng Dengyu
Xu Bo
Liu Xin
Wang Yajun
Ye Fei
TANG Pingming
Ni Jia
Zhang Chen
Yan Pangke
Original Assignee
Haisco Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haisco Pharmaceuticals Pte Ltd filed Critical Haisco Pharmaceuticals Pte Ltd
Publication of CL2023000532A1 publication Critical patent/CL2023000532A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe un compuesto derivado de nitrilo representado por la fórmula (I), un estereoisómero, un producto deuterado, un cocristal, un solvato o una sal farmacéuticamente aceptable del mismo, en donde cada grupo es como se define en la descripción. El compuesto tiene actividad inhibidora de la dipeptidil peptidasa 1 y puede usarse para preparar un fármaco para tratar enfermedades que incluyen enfermedades obstructivas de las vías respiratorias, bronquiectasias, fibrosis quística, asma, enfisema y enfermedades pulmonares obstructivas crónicas.
CL2023000532A 2020-08-26 2023-02-23 Derivado de nitrilo que actúa como inhibidor de la dipeptidil peptidasa 1 y su uso CL2023000532A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010871912 2020-08-26
CN202011129809 2020-10-21
CN202110167731 2021-02-07

Publications (1)

Publication Number Publication Date
CL2023000532A1 true CL2023000532A1 (es) 2023-09-29

Family

ID=80354645

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000532A CL2023000532A1 (es) 2020-08-26 2023-02-23 Derivado de nitrilo que actúa como inhibidor de la dipeptidil peptidasa 1 y su uso

Country Status (13)

Country Link
US (2) US11807635B2 (es)
EP (1) EP4129989B1 (es)
JP (1) JP2023539101A (es)
KR (1) KR20230084134A (es)
CN (1) CN115996923A (es)
AU (1) AU2021330865B2 (es)
BR (1) BR112023003492A2 (es)
CA (1) CA3190610A1 (es)
CL (1) CL2023000532A1 (es)
IL (1) IL300855A (es)
MX (1) MX2023002371A (es)
TW (1) TW202214616A (es)
WO (1) WO2022042591A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022011917A2 (pt) 2019-12-20 2022-09-06 Tenaya Therapeutics Inc Fluoroalquil-oxadiazois e seus usos
WO2023160542A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型
MX2024010176A (es) * 2022-02-22 2024-08-27 Haisco Pharmaceuticals Pte Ltd Metodo de preparacion de un compuesto heterociclico que contiene nitrogeno.
WO2024192416A1 (en) * 2023-03-16 2024-09-19 Insmed Incorporated Dpp1 inhibitors with polycyclic linkers and uses thereof
WO2024193695A1 (zh) * 2023-03-23 2024-09-26 西藏海思科制药有限公司 一种二肽基肽酶小分子抑制剂的药物组合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
WO2003048123A1 (en) 2001-12-04 2003-06-12 F. Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
EP1638925A1 (en) 2003-06-18 2006-03-29 Prozymex A/S Protease inhibitors
AU2008334444B2 (en) * 2007-12-12 2011-12-15 Astrazeneca Ab Peptidyl nitriles and use thereof as dipeptidyl peptidase I inhibitors
CA2759581A1 (en) * 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
AU2010319927B2 (en) * 2009-10-29 2015-01-22 Janssen Pharmaceutica Nv Alkynyl derivatives useful as DPP-1 inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
WO2015032942A1 (en) * 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
NO2699580T3 (es) * 2014-01-24 2018-02-24
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
WO2016139355A1 (en) * 2015-03-05 2016-09-09 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
US10526287B2 (en) 2015-04-23 2020-01-07 Constellation Pharmaceuticals, Inc. LSD1 inhibitors and uses thereof
CN107922315B (zh) 2015-08-29 2021-03-26 广东东阳光药业有限公司 组织蛋白酶k抑制剂及其用途
JP2021512904A (ja) * 2018-02-07 2021-05-20 インスメッド インコーポレイテッド Ａｎｃａ関連血管炎の治療のためのある種の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニル］−１，４−オキサゼパン−２−カルボキサミド

Also Published As

Publication number Publication date
EP4129989A1 (en) 2023-02-08
TW202214616A (zh) 2022-04-16
AU2021330865B2 (en) 2024-07-18
JP2023539101A (ja) 2023-09-13
US20230121807A1 (en) 2023-04-20
BR112023003492A2 (pt) 2023-05-09
US20240059681A1 (en) 2024-02-22
US11807635B2 (en) 2023-11-07
EP4129989B1 (en) 2024-10-02
IL300855A (en) 2023-04-01
EP4129989A4 (en) 2024-06-05
MX2023002371A (es) 2023-05-19
CN115996923A (zh) 2023-04-21
CA3190610A1 (en) 2022-03-03
KR20230084134A (ko) 2023-06-12
WO2022042591A1 (zh) 2022-03-03
AU2021330865A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
CL2023000532A1 (es) Derivado de nitrilo que actúa como inhibidor de la dipeptidil peptidasa 1 y su uso
CO2021013140A2 (es) Derivado de pirazina y aplicación del mismo en la inhibición de shp2
MX2019004018A (es) Pirrolidinas sustituidas y sus usos en el tratamiento de la fibrosis quistica.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2019008986A2 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
CR20160327A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
EA201591978A1 (ru) 3,5-диамино-6-хлор-n-(n-(4-(4-(2-(гексил(2,3,4,5,6-пентагидроксигексил)амино)этокси)фенил)бутил)- карбамимидоил)пиразин-2-карбоксамид
CL2013002737A1 (es) Acido 4-((4-((((1r, 2s)-2-fenilciclopropil)amino)metil)piperidin-1-il)metil)benzoico con actividad inhibidora de desmetilasa 1 especifica de lisina (lsd1); composicion farmaceutica que lo comprende, utiles en el tratamiento del cancer.
CL2020001090A1 (es) Compuesto de pirimidina como inhibidor de las janocinasas.
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
DOP2006000170A (es) Nuevos derivados de espirocromanona
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
MX2022014971A (es) D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso.
CL2020002939A1 (es) Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
MX2024005747A (es) Benzamidas de derivados de pirazolil-amino-pirimidinilo y composiciones y metodos de las mismas.
PE20070828A1 (es) Composicion farmaceutica que contiene una sal de glicopirronio
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
AR119318A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
AR127501A1 (es) Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak